Compare Gilead Sciences, Inc. (GILD) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Raymond James Financial, Inc. — how do they compare? Gilead Sciences, Inc. trades at $132.91 (market cap $163.51B), while Raymond James Financial, Inc. trades at $169.54 (market cap $33.19B). The key difference: Gilead Sciences, Inc. is far larger — about 4.9× Raymond James Financial, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | RJF | |
|---|---|---|
Market Cap | $163.51B | $33.19B |
Sector | Health | Financials |
52-Week High | $155.80 | $176.43 |
52-Week Low | $108.22 | $140.89 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Raymond James Financial (RJF) trades at $167.43, up 0.27% today, with a bullish technical signal and consistent earnings beats. Revenue grew to $13.84B in 2025, though net income margin dipped slightly to 15.42%. The stock is supported by a consensus price target of $176.83 and a declared $0.54 dividend payable in July 2026.
The outlook remains positive with strong analyst support and record revenues, but rising expenses and a high RSI near 75 indicate potential near-term volatility. Long-term growth is supported by advisor expansion and strategic acquisitions, though cost management remains a key focus for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
